CLINICAL_TRIALS
trial_result
· 2020-01-14
Clinical Trial Update: Safety of Switching From Rituximab to Ocrelizumab in MS Patients [Phase 3]
Summary
Clinical trial update evaluating safety of switching from Rituximab to Ocrelizumab in multiple sclerosis patients (Phase 3).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Colorado, Denver | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2020-01-14